The aim of the present study was to investigate, if increased levels of apoB/apoA-I ratios are associated with future peripheral arterial disease as measured by ankle-brachial index. Increased apoB/apoA-I levels are defined as 0.9, which has been suggested for men, and as 0.63, which has observed to be associated with plaques in the femoral artery. The study was performed in a cohort of initially clinically healthy 58-year-old men living in the city of Göteborg, Sweden. The group with an apoB/apoA-I ratio ≥0.9 had a significantly increased risk of having PAD during 8.9 years of follow-up than the group below that level (OR: 2.15 CI: 1.21 to 3.82, p < 0.01). When applying the lower apoB/apoA-I cut off, results showed that the group with a level >0.63 had more than a three-fold risk of future PAD compared to the group ≤0.63 (OR: 3.28 CI: 1.14 to 9.40, p < 0.05).
American Heart Association.Heart Disease and Stroke Statistics—2004 Update. (1st ed.) Dallas, TX: American Heart Association; 2003: 20–22.
2.
SchroderF., DihemN., KareemS.A modified calculation of ankle-brachial index is far more sensitive in the detection of peripheral arterial disease.J Vasc Surg.2006; 44: 531–536.
WallenfeldtK., BokemarkL., WikstrandJ., HultheJ., FagerbergB.Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men.Stroke.2004; 35: 2248–2252.
5.
WalldiusG., JungnerI.Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I—new risk factors and targets for therapy.Nutr, Metab Cardiovasc Dis.2007; 17: 565–571.
6.
WalldiusG., JungnerI.Apolipoprotein B and Apolipoprotein A-I: risk indicators of coronary heart disease and targets of lipid-modifying therapy.J Int Med.2004; 255: 188–205.
7.
WalldiusG., JungnerI., HolmeI., AastveitA.H., KolarW., SteinerE.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.Lancet.2001; 358: 2026–2033.
8.
JadhavU.M., KadamN.N.Apolipoproteins: correlation with carotid intimamedia thickness and coronary artery disease.J Assoc Physicians India.2004; 52: 370–375.
9.
RasouliM., KiasariA.M., MokhberiV.The ratio of apoB/apoA-I and lipoprotein (a) are the best predictors of stable coronary artery disease.Clin Chem Lab Med.2006; 44: 1015–1021.
10.
Van der SteegW.A., BoekholdtS.M., SteinE.A.Role of the Apolipoprotein B—Apolipoprotein A-I in cardiovascular risk assessment: a case-control analysis in EPIC—Norfolk.Ann Int Med.2007; 146: 640–648.
11.
VaverkovaH., FrohlichJ., JackuliakovaD., NovontyD.Comparison of apolipoprotein B and plasma lipids as target for lipid lowering treatment.Clin Biochem.2005; 38: 509–513.
12.
Roeters Van LennepJ.E., WerterveldT., Roeters Van LennepH.W.O.Apolipoprotein concentrations during treatment and recurrent coronary artery disease events.Arterioscler Thromb Vasc Biol.2000; 20: 2408–2413.
13.
SnidermanA.D., FurbergC.D., KeechA.Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.Lancet.2003; 361: 777–780.
14.
WagnerA.M., Ordonez-LlanosJ.Apolipoproteins and predictions of fatal myocardial infarction.Lancet.2002; 359: 1863–1864.
15.
WalldiusG., JungnerI.The apo B/apo A-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence.J Intern Med.2006; 259: 493–519.
16.
SnidermanA.D., JungnerI., HolmeI., AastveitA., WalldiusG.Error that result from the TC/HDL C ratio rather than the apo B/apo A-I ratio to identify the lipoprotein-related risk of vascular disease.J Intern Med.2006; 259: 455–461.
17.
LamarcheB., MoorjaniS., LupienP.J.Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study.Circulation.1996; 94: 273–278.
18.
MossA.J., GoldsteinR.E., MarderV.J.Thrombogenic factors and recurrent coronary events.Circulation.199; 99: 2517–2522.
19.
TalmudP.J., HaweE., MillerG.J., HumphriesS.E.Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease events.Arterioscler Thromb Vasc Biol.2002; 22: 1918–1923.
20.
SchmidtC., FagerbergB.ApoB/apoA-I ratio is related to femoral artery plaques in 64-year-old women, also in cases with low LDL cholesterol.Atherosclerosis.2008; 196: 817–822.
21.
SimesR.J., MarschnerI.C., HuntD.Relationship between lipids levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial.Circulation.2002; 105: 1162–1169.
22.
PowellJ.T., EdwardsR.J., WorrellP.C., FranksP.J., GreenhalghR.M., PoulterN.R.Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study.Atherosclerosis.1997; 129: 41–48.
23.
AngquistK.A., JohnsonO., EricssonM., TollinC.Serum lipoproteins and apolipoproteins AI and AII in male patients with peripheral arterial insufficiency.Acta Chir Scand.1982; 148: 675–678.
24.
ÓNealD.N., LewickiJ., AnsariM.Z., MatthewsP.G., BestJ.D.Lipids levels and peripheral vascular disease in diabetic and non-diabetic subjects.Atherosclerosis.1998; 136: 1–8.
25.
BradbyG.V., ValenteA.J., WaltonK.W.Serum high density lipoproteins in peripheral vascular disease.Lancet.1978; 8103: 1271–1274.
26.
PilgerE., PristautzH., PfeifferK.H., KostnerG.Retrospective evaluation of risk factors for peripheral atherosclerosis by stepwise discriminant analysis.Atherosclerosis.1983; 3: 57–63.
27.
SuurkülaM., FagerbergB., WendelhagI., AgewallS., WikstrandJ.Atherosclerotic disease in the femoral artery in hypertensive patients at high cardiovascular risk. The value of ultrasonographic assessment of intima-media thickness and plaque occurrence. Risk Intervention Study (RIS) Group.Arterioscler Thromb Vasc Biol.1996; 16: 971–977.
28.
BokemarkL., WikstrandJ., WedelH., FagerbergB.Insulin, insulin properties and intima-media thickness in carotid artery in 58-year-old clinically healthy men. The atherosclerosis and insulin resistance study (AIR).Diabetic Med.2002; 19: 144–151.
29.
SchmidtC., FagerbergB., HultheJ.Non-stenotic ultrasound-assessed femoral artery plaques are predictive for future cardiovascular events in middle-aged men.Atherosclerosis.2005; 18: 25–30.
30.
WallenfeldtK., HultheJ., BokemarkL., WikstrandJ., FagerbergB.Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men.J Intern Med.2001; 250: 492–501.
31.
SchmidtC., FagerbergB., WikstrandJ., HultheJ.ApoB/apoA-I is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men.Atherosclerosis.2006; 189: 178–185.
32.
TivestenÅ, HultheJ., WallenfeldtK., WikstrandJ., OhlssonC., FagerbergB.Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men.Clin Endocrinol Metab.2006; 91: 4433–4437.
33.
SnidermanA.D., JungnerI., AasteitA.H., WallidiusG.Errors that result from the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.J Intern Med.2006; 259: 455–461.
34.
WalldiusG., JungnerI., AasteveitA., HolmeI., FurbergC.D., SnidermanA.D.The apoB/apoA-I ratio is better than cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.Clin Chem Lab Med.2004; 42: 1355–1363.
35.
SchmidtC., FagerbergB., WikstrandJ., HultheJ.ApoB/apoA-I is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men.Atherosclerosis.2005; 189: 178–185.
36.
CuiR., IsoH., YamagishiK., TanigawaT.Relationship of smoking and smoking cessation with ankle-to-arm blood pressure index in elderly Japanese men.Eur J Cardiovasc Prev Rehabil.2006; 13: 243–248.
37.
NewmanA.B., SiscovickD.S., ManolioT.A.Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Healthy Study.Circulation.1993; 88: 837–845.
38.
MeijerW.T., GrobbeeD.E., HuninkM.G., HofmanA., HoesA.W.Determinants of peripheral arterial disease in the elderly: the Rotterdam study.Arch Intern Med.2000; 160: 2934–2938.
39.
CoppolaG., NovoS.Statins and peripheral arterial disease: effects on claudication, disease progression and prevention of cardiovascular events.Arch Med Res.2007; 38: 479–488.
40.
BuchwaldH., VarcoR.L., BoenJ.R.Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH.Arch Intern Med.1998; 158: 1253–1261.
41.
AungP.P., MaxwellH.G., JepsonR.G., PriceJ.F., LengG.C.Lipid-lowering for peripheral arterial disease of the lower limb.Cochrane Database Syst Rev.2007; 4: CD000123.
42.
RifaiC.J., BachorikP.S., AlberttJ.J.Lipids, lipoproteins and apolipoproteins. In: BuritsC.A., AshwoodE.R. eds. Tietz—Textbook of Clinical Chemistry.3rd ed.Philadelphia, PA: Saunders; 1999; 809–861.
